Progress on RNAi-based molecular medicines

International Journal of Nanomedicine

Volumn 7, Issue , 2012, Pages 3971-3980

  Chen, Jing ^a   Xie, Jianping ^a  

^a SOUTHWEST UNIVERSITY   (China)

Author keywords

Delivery systems; Liposome; Molecular medicines; Nanoparticle; RNA interference

Indexed keywords

GOLD NANOPARTICLE; SMALL INTERFERING RNA;

BACTERIOPHAGE; CLINICAL TRIAL (TOPIC); DRUG TARGETING; GENE CASSETTE; GENE DELIVERY SYSTEM; GENE EXPRESSION; GENE IDENTIFICATION; GENE LIBRARY; GENE TARGETING; GENETIC TRANSFECTION; HUMAN; LIPOSOMAL GENE DELIVERY SYSTEM; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; REVIEW; RNA INTERFERENCE; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; DRUG DELIVERY SYSTEMS; HUMANS; LIPOSOMES; MOLECULAR MEDICINE; NANOPARTICLES; RNA INTERFERENCE;

RABIES VIRUS;

EID: 84870358483     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S31897     Document Type: Review

References (117)

1. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature. 1998;391(6669):806-811.
2. Hannon GJ. RNA interference. Nature. 2002;418(6894):244-251.
3. Meister G, Tuschl T. Mechanisms of gene silencing by double-stranded RNA. Nature. 2004;431(7006):343-349.
4. Novina CD, Sharp PA. The RNAi revolution. Nature. 2004;430(6996): 161-164.
5. Pushparaj PN, Aarthi JJ, Manikandan J, Kumar SD. siRNA, miRNA, and shRNA: in vivo applications. J Dent Res. 2008;87(11):992-1003.
6. Davidson BL, McCray PB Jr. Current prospects for RNA interference-based therapies. Nat Rev Genet. 2011;12(5):329-340.
7. Valencia-Sanchez MA, Liu J, Hannon GJ, Parker R. Control of translation and mRNA degradation by miRNAs and siRNAs. Genes Dev. 2006;20(5):515-524.
8. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2):281-297.
9. Lund E, Sheets MD, Imboden SB, Dahlberg JE. Limiting Ago protein restricts RNAi and microRNA biogenesis during early development in Xenopus laevis. Genes Dev. 2011;25(11):1121-1131.
10. Elbashir SM, Lendeckel W, Tuschl T. RNA interference is mediated by 21-and 22-nucleotide RNAs. Genes Dev. 2001;15(2):188-200.
11. Zamore PD, Tuschl T, Sharp PA, Bartel DP. RNAi: double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals. Cell. 2000;101(1):25-33.
12. Lewis BP, Shih IH, Jones-Rhoades MW, Bartel DP, Burge CB. Prediction of mammalian microRNA targets. Cell. 2003;115(7):787-798.
13. Eulalio A, Huntzinger E, Izaurralde E. Getting to the root of miRNA-mediated gene silencing. Cell. 2008;132(1):9-14.
14. Fabian MR, Sonenberg N, Filipowicz W. Regulation of mRNA translation and stability by microRNAs. Annu Rev Biochem. 2010;79:351-379.
15. Bhattacharyya SN, Habermacher R, Martine U, Closs EI, Filipowicz W. Relief of microRNA-mediated translational repression in human cells subjected to stress. Cell. 2006;125(6):1111-1124.
16. Liu G, Wong-Staal F, Li QX. Recent development of RNAi in drug target discovery and validation. Drug Discov Today Technol. 2006;3(3): 293-300.
17. Elbashir SM, Harborth J, Weber K, Tuschl T. Analysis of gene function in somatic mammalian cells using small interfering RNAs. Methods. 2002;26(2):199-213.
18. Lina W, Chonggang Y. Development and applications of RNAi technology in drug research. Chin Bull Life Sci. 2007;19:199-213.
19. Reynolds A, Leake D, Boese Q, Scaringe S, Marshall WS, Khvorova A. Rational siRNA design for RNA interference. Nat Biotechnol. 2004;22(3):326-330.
20. Harborth J, Elbashir SM, Vandenburgh K, etal. Sequence, chemical, and structural variation of small interfering RNAs and short hairpin RNAs and the effect on mammalian gene silencing. Antisense Nucleic Acid Drug Dev. 2003;13(2):83-105.
21. Shirane D, Sugao K, Namiki S, Tanabe M, Iino M, Hirose K. Enzymatic production of RNAi libraries from cDNAs. Nat Genet. 2004;36(2): 190-196.
22. Herold MJ, van den Brandt J, Seibler J, Reichardt HM. Inducible and reversible gene silencing by stable integration of an shRNA-encoding lentivirus in transgenic rats. Proc Natl Acad Sci U S A. 2008;105(47): 18507-18512.
23. Li J, Huang L. Targeted delivery of RNAi therapeutics for cancer therapy. Nanomedicine (Lond). 2010;5(10):1483-1486.
24. Tuschl T. Expanding small RNA interference. Nat Biotechnol. 2002; 20(5):446-448.
25. Brummelkamp TR, Bernards R, Agami R. A system for stable expression of short interfering RNAs in mammalian cells. Science. 2002; 296(5567):550-553.
26. Tiscornia G, Singer O, Ikawa M, Verma IM. A general method for gene knockdown in mice by using lentiviral vectors expressing small interfering RNA. Proc Natl Acad Sci U S A. 2003;100(4):1844-1848.
27. Rubinson DA, Dillon CP, Kwiatkowski AV, etal. A lentivirus-based system to functionally silence genes in primary mammalian cells, stem cells and transgenic mice by RNA interference. Nat Genet. 2003;33(3): 401-406.
28. Chen Z, Stockton J, Mathis D, Benoist C. Modeling CTLA4-linked autoimmunity with RNA interference in mice. Proc Natl Acad Sci U S A. 2006;103(44):16400-16405.
29. Matsukura S, Jones PA, Takai D. Establishment of conditional vectors for hairpin siRNA knockdowns. Nucleic Acids Res. 2003;31(15):e77.
30. Sheng Y, Lin CC, Yue J, etal. Generation and characterization of a Tet-On (rtTA-M2) transgenic rat. BMC Dev Biol. 2010;10:17.
31. Seibler J, Kleinridders A, Küter-Luks B, Niehaves S, Brüning JC, Schwenk F. Reversible gene knockdown in mice using a tight, inducible shRNA expression system. Nucleic Acids Res. 2007;35(7):e54.
32. Anastassiadis K, Kim J, Daigle N, Sprengel R, Schöler HR, Stewart AF. A predictable ligand regulated expression strategy for stably integrated transgenes in mammalian cells in culture. Gene. 2002;298(2):159-172.
33. Szymczak AL, Vignali DA. Development of 2A peptide-based strategies in the design of multicistronic vectors. Expert Opin Biol Ther. 2005;5(5):627-638.
34. Abdelmawla S, Guo S, Zhang L, etal. Pharmacological characterization of chemically synthesized monomeric phi29 pRNA nanoparticles for systemic delivery. Mol Ther. 2011;19(7):1312-1322.
35. Woodle MC, Lu PY. Nanoparticles deliver RNAi therapy. Mater Today. 2005;8(8 Suppl 1):34-41.
36. Allen TM, Cullis PR. Drug delivery systems: entering the mainstream. Science. 2004;303(5665):1818-1822.
37. van den Boorn JG, Schlee M, Coch C, Hartmann G. SiRNA delivery with exosome nanoparticles. Nat Biotechnol. 2011;29(4):325-326.
38. Lares MR, Rossi JJ, Ouellet DL. RNAi and small interfering RNAs in human disease therapeutic applications. Trends Biotechnol. 2010; 28(11):570-579.
39. Sutton D, Kim S, Shuai X, etal. Efficient suppression of secretory clusterin levels by polymer-siRNA nanocomplexes enhances ionizing radiation lethality in human MCF-7 breast cancer cells in vitro. Int J Nanomedicine. 2006;1(2):155-162.
40. Wu Y, Wang W, Chen Y, etal. The investigation of polymer-siRNA nanoparticle for gene therapy of gastric cancer in vitro. Int J Nanomedicine. 2010;5:129-136.
41. Yamamichi K, Uehara Y, Kitamura N, Nakane Y, Hioki K. Increased expression of CD44v6mRNA significantly correlates with distant metastasis and poor prognosis in gastric cancer. Int J Cancer. 1998; 79(3):256-262.
42. Kurozumi K, Nishida T, Nakao K, Nakahara M, Tsujimoto M. Expression of CD44 variant 6 and lymphatic invasion: importance to lymph node metastasis in gastric cancer. World J Surg. 1998;22(8):853-857.
43. Miyoshi H, Blomer U, Takahashi M, Gage FH, Verma IM. Development of a self-inactivating lentivirus vector. J Virol. 1998;72(10): 8150-8157.
44. VandenDriessche T, Thorrez L, Naldini L, etal. Lentiviral vectors containing the human immunodeficiency virus type-1 central polypurine tract can efficiently transduce nondividing hepatocytes and antigen-presenting cells in vivo. Blood. 2002;100(3):813-822.
45. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, etal. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science. 2003;302(5644):415-419.
46. Hannon GJ, Rossi JJ. Unlocking the potential of the human genome with RNA interference. Nature. 2004;431(7006):371-378.
47. Raoul C, Abbas-Terki T, Bensadoun JC, etal. Lentiviral-mediated silencing of SOD1 through RNA interference retards disease onset and progression in a mouse model of ALS. Nat Med. 2005;11(43):423-428.
48. McKinley MP, Bolton DC, Prusiner SB. A protease-resistant protein is a structural component of the Scrapie prion. Cell. 1983;35(1):57-62.
49. Bolton D, McKinley M, Prusiner S. Identification of a protein that purifies with the scrapie prion. Science. 1982;218(4579):1309-1311.
50. Giese A, Brown DR, Groschup MH, Feldmann C, Haist I, Kretzschmar HA. Role of microglia in neuronal cell death in prion disease. Brain Pathol. 1998;8(3):449-457.
51. Bueler H, Raeber A, Sailer A, Fischer M, Aguzzi A, Weissmann C. High prion and PrPSc levels but delayed onset of disease in scrapie-inoculated mice heterozygous for a disrupted PrP gene. Mol Med. 1994; 1(1):19-30.
52. Pfeifer A, Eigenbrod S, Al-Khadra S, etal. Lentivector-mediated RNAi efficiently suppresses prion protein and prolongs survival of scrapie-infected mice. J Clin Invest. 2006;116(12):3204-3210.
53. Mallucci G, Dickinson A, Linehan J, Klöhn PC, Brandner S, Collinge J. Depleting neuronal PrP in prion infection prevents disease and reverses spongiosis. Science. 2003;302(5646):871-874.
54. Gallozzi M, Chapuis J, Le Provost F, etal. Prnp knockdown in transgenic mice using RNA interference. Transgenic Res. 2008;17(5):783-791.
55. Pulford B, Reim N, Bell A, etal. Liposome-siRNA-peptide complexes cross the blood-brain barrier and significantly decrease PrP on neuronal cells and PrP in infected cell cultures. PLoS One. 2010;5(6):e11085.
56. Berger EA, Murphy PM, Farber JM. Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Ann Rev Immunol. 1999;17(1):657-700.
57. Moore JP, Trkola A, Dragic T. Co-receptors for HIV-1 entry. Curr Opin Immunol. 1997;9(4):551-562.
58. Mosier D. Virus and target cell evolution in human immunodeficiency virus type 1 infection. Immunol Res. 2000;21(2):253-258.
59. Simmons G, Reeves JD, Hibbitts S, etal. Co-receptor use by HIV and inhibition of HIV infection by chemokine receptor ligands. Immunol Rev. 2000;177(1):112-126.
60. O'Brien SJ, Nelson GW. Human genes that limit AIDS. Nat Genet. 2004;36(6):565-574.
61. Smith MW, Dean M, Carrington M, etal. Contrasting genetic influence of CCR2 and CCR5 variants on HIV-1infection and disease progression. Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC), ALIVE Study. Science. 1997;277(5328):959-965.
62. Shimizu S, Hong P, Arumugam B, etal. A highly efficient short hairpin RNA potently down-regulates CCR5 expression in systemic lymphoid organs in the hu-BLT mouse model. Blood. 2010;115(8):1534-1544.
63. Zhang S, Zhao B, Jiang H, Wang B, Ma B. Cationic lipids and polymers mediated vectors for delivery of siRNA. J Control Release. 2007;123(1):1-10.
64. Andersen MO, Howard KA, Paludan SR, Besenbacher F, Kjems J. Delivery of siRNA from lyophilized polymeric surfaces. Biomaterials. 2008;29(4):506-512.
65. Kumar P, Wu H, McBride JL, etal. Transvascular delivery of small interfering RNA to the central nervous system. Nature. 2007;448(7149): 39-43.
66. Lafon M. Rabies virus receptors. J Neurovirol. 2005;11(1):82-87.
67. Morrissey DV, Lockridge JA, Shaw L, etal. Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat Biotechnol. 2005;23(8):1002-1007.
68. Richards D, Ivanisevic A. Inorganic material coatings and their effect on cytotoxicity. Chem Soc Rev. 2012;41(6):2052-2060.
69. Rippel RA, Seifalian AM. Gold revolution-gold nanoparticles for modern medicine and surgery. J Nanosci Nanotechnol. 2011;11(5): 3740-3748.
70. Ghosh P, Han G, De M, Kim CK, Rotello VM. Gold nanoparticles in delivery applications. Adv Drug Deliv Rev. 2008;60(11):1307-1315.
71. Guo S, Huang Y, Jiang Q, etal. Enhanced gene delivery and siRNA silencing by gold nanoparticles coated with charge-reversal polyelectrolyte. ACS Nano. 2010;4(9):5505-5511.
72. Chen AM, Taratula O, Wei D, etal. Labile catalytic packaging of DNA/siRNA: control of gold nanoparticles "out" of DNA/siRNA complexes. ACS Nano. 2010;4(7):3679-3688.
73. Thomas M, Klibanov AM. Conjugation to gold nanoparticles enhances polyethylenimine's transfer of plasmid DNA into mammalian cells. Proc Natl Acad Sci U S A. 2003;100(16):9138-9143.
74. Rosi NL, Giljohann DA, Thaxton CS, Lytton-Jean AKR, Han MS, Mirkin CA. Oligonucleotide-modified gold nanoparticles for intracellular gene regulation. Science. 2006;312(5776):1027-1030.
75. Elbakry A, Zaky A, Liebl R, Rachel R, Goepferich A, Breunig M. Layer-by-layer assembled gold nanoparticles for siRNA delivery. Nano Lett. 2009;9(5):2059-2064.
76. Lee JS, Green JJ, Love KT, Sunshine J, Langer R, Anderson DG. Gold, poly(beta-amino ester) nanoparticles for small interfering RNA delivery. Nano Lett. 2009;9(6):2402-2406.
77. Song WJ, Du JZ, Sun TM, Zhang PZ, Wang J. Gold nanoparticles capped with polyethyleneimine for enhanced siRNA delivery. Small. 2010;6(2):239-246.
78. Zuckerman JE, Choi CHJ, Han H, Davis ME. Polycation-siRNA nanoparticles can disassemble at the kidney glomerular basement membrane. Proc Natl Acad Sci U S A. 2012;109(8):3137-3142.
79. Kong W, Bae K, Jo S, Kim J, Park T. Cationic lipid-coated gold nanoparticles as efficient and non-cytotoxic intracellular siRNA delivery vehicles. Pharm Res. 2012;29(2):362-374.
80. Sokolov K, Follen M, Aaron J, etal. Real-time vital optical imaging of precancer using anti-epidermal growth factor receptor antibodies conjugated to gold nanoparticles. Cancer Res. 2003;63(9):1999-2004.
81. Xi D, Luo X, Ning Q, Lu Q, Yao K, Liu Z. The detection of HBV DNA with gold nanoparticle gene probes. Journal of Nanjing Medical University. 2007;21(4):207-212.
82. Baptista PV, Koziol-Montewka M, Paluch-Oles J, Doria G, Franco R. Gold nanoparticle probe-based assay for rapid and direct detection of Mycobacterium tuberculosis DNA in clinical samples. Clin Chem. 2006;52(7):1433-1434.
83. Georganopoulou DG, Chang L, Nam JM, etal. Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer's disease. Proc Natl Acad Sci U S A. 2005;102(7): 2273-2276.
84. Mahmoud KA, Luong JHT. Impedance method for detecting HIV-1 protease and screening for its inhibitors using ferrocene-peptide conjugate/Au nanoparticle/single-walled carbon nanotube modified electrode. Anal Chem. 2008;80(18):7056-7062.
85. Guo P, Erickson S, Anderson D. A small viral RNA is required for in vitro packaging of bacteriophage phi 29 DNA. Science. 1987;236(4802): 690-694.
86. Hoeprich S, Guo P. Computer modeling of three-dimensional structure of DNA-packaging RNA (pRNA) monomer, dimer, and hexamer of Phi29 DNA packaging motor. J Biol Chem. 2002;277(23): 20794-20803.
87. Khaled A, Guo S, Li F, Guo P. Controllable self-assembly of nanoparticles for specific delivery of multiple therapeutic molecules to cancer cells using RNA nanotechnology. Nano Lett. 2005;5(9):1797-1808.
88. Chen C, Sheng S, Shao Z, Guo P. A dimer as a building block in assembling RNA. J Biol Chem. 2000;275(23):17510-17516.
89. Zhang C, Lee CS, Guo P. The proximate 5' and 3' ends of the 120-base viral RNA (pRNA) are crucial for the packaging of bacteriophage Ø29 DNA. Virology. 1994;201(1):77-85.
90. Garver K, Guo P. Boundary of pRNA functional domains and minimum pRNA sequence requirement for specific connector binding and DNA packaging of phage phi29. RNA. 1997;3(9):1068-1079.
91. Reid RJ, Bodley JW, Anderson D. Characterization of the prohead-pRNA interaction of bacteriophage phi 29. J Biol Chem. 1994;269(7): 5157-5162.
92. Chen C, Zhang C, Guo P. Sequence requirement for hand-in-hand interaction in formation of RNA dimers and hexamers to gear phi29 DNA translocation motor. RNA. 1999;5(6):805-818.
93. Zhang C, Trottier M, Guo P. Circularly permuted viral pRNA active and specific in the packaging of bacteriophage φ{symbol}29 DNA. Virology. 1995;207(2):442-451.
94. Guo S, Tschammer N, Mohammed S, Guo P. Specific delivery of therapeutic RNAs to cancer cells via the dimerization mechanism of phi29 motor pRNA. Hum Gene Ther. 2005;16(9):1097-1109.
95. Guo S, Huang F, Guo P. Construction of folate-conjugated pRNA of bacteriophage phi29 DNA packaging motor for delivery of chimeric siRNA to nasopharyngeal carcinoma cells. Gene Ther. 2006;13(10):814-820.
96. Liu J, Guo S, Cinier M, etal. Fabrication of stable and RNase-resistant RNA nanoparticles active in gearing the nanomotors for viral DNA packaging. ACS Nano. 2010;5(1):237-246.
97. Davis ME, Zuckerman JE, Choi CHJ, etal. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature. 2010;464(7291):1067-1070.
98. Kim SS, Peer D, Kumar P, etal. RNAi-mediated CCR5silencing by LFA-1-targeted nanoparticles prevents HIV infection in BLT mice. Mol Ther. 2010;18(2):370-376.
99. Xinping L. Applications of RNA interference technology to drug study. Chinese Pharmacological Bulletin. 2005;21(4):400-403.
100. TheFreeLibrary. com [homepage on the Internet]. OPKO Health Announces Update on Phase III Clinical Trial of Bevasiranib. Pennsylvania: Farlex, Inc.; c 2012 [updated 2009 May 6; cited 2012 Apr 10]. Available from: http://www.thefreelibrary.com/OPKO+Health+Announces+Update+on+Phase+III+Clinical+Trial+of.-a0195014938. Accessed Jun 25, 2012.
101. Quarkpharma. com [homepage on the Internet]. Quark Pharmaceuticals Presented At ARVO Data Showing That PF-04523655 Enters Retinal Cells And Elicits Its Pharmacologic Effect Via Target Gene Knock-Down Without Activating TLR3. California: Quark Pharmaceuticals, Inc.; c 2007 [updated 2009 May 11; cited 2012 Apr 10]. Available from: http://www.quarkpharma.com/qbi-en/newslist/arvo/. Accessed Jun 25, 2012.
102. Tekmirapharm. com [homepage on the Internet]. Tekmira Provides Corporate Update and Announces First Quarter 2012 Results. British Columbia: Tekmira Pharmaceuticals Corp.; c 2012 [updated 2012 May 15; cited 2012 Apr 10]. Available from: http://investor.tekmirapharm.com/releasedetail.cfm?releaseid=673804. Accessed Jun 22, 2012.
103. Tekmirapharm. com [homepage on the Internet]. Tekmira Announces Initiation of TKM-Ebola Phase 1 Clinical Trial British Columbia: Tekmira Pharmaceuticals Corp.; c 2012 [updated 2012 Feb 8; cited 2012 Apr 10]. Available from: http://files.shareholder.com/downloads/ABEA-50QJTB/1754071349x0x541056/d731bed8-39f3-4fe2-a962-c86e2f72e681/TKMR_News_2012_2_8_General_Releases.pdf. Accessed Jun 24, 2012.
104. Pharmaceuticals A. Phase 2b Study of ALN-RSV01 in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV). In: ClinicalTrials. gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; 2012 [updated 2012 May 30]. Available from: http://clinicaltrials.gov/ct2/show/NCT01065935?term=Alnylam&rank=5. ClinicalTrials.gov Identifier: NCT01065935. Accessed Jul 11, 2012.
105. Quarkpharma. com [homepage on the Internet]. Quark Pharmaceuticals Reports Favorable Interim Results from Phase I Clinical Study of QPI-1007 California: Quark Pharmaceuticals, Inc.; c 2007 [updated 2012 Jan 4; cited 2012 Apr 10]. Available from: http://www.quarkpharma.com/qbi-en/newslist/clinicalstudyqpi-1007/. Accessed Jun 21, 2012.
106. Pharmaceuticals A. Dose Escalation Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous ALN-VSP02 In Patients With Advanced Solid Tumors With Liver Involvement. In: ClinicalTrials. gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; 2011 [updated 2011 Aug 23]. Available from: http://clinicaltrials.gov/ct2/show/NCT00882180?term=Alnylam&rank= 3. ClinicalTrials.gov Identifier: NCT00882180. Accessed Jul 11, 2012.
107. Calando. com [homepage on the Internet]. Arrowhead Research Subsidiary, Calando Pharmaceuticals, Provides First Proof of RNA Interference in Humans with Systemically Administered siRNA Therapeutic; Clinical Trial Results Published in Nature California: Calando Pharmaceuticals; c 2012 [updated 2010 Mar 22; cited 2012 Apr 11]. Available from: http://www.calandopharma.com/newspdfs/NR--Calando_data--3-22-10_final.pdf. Accessed Jun 19, 2012.
108. Project PC. Study of TD101, a Small Interfering RNA (siRNA) Designed for Treatment of Pachyonychia Congenita. In: ClinicalTrials. gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; 2008 [updated 2008 Nov 18]. Available from: http://clinicaltrials.gov/ct2/show/NCT00716014. ClinicalTrials.gov Identifier: NCT00716014. Accessed Jul 11, 2012.
109. Genomeweb. com [homepage on the Internet]. Allergan Drops Development of siRNA Rx for AMD on Poor Phase II Data. New York: GenomeWeb LLC.; c 2012 [updated 2009 May 28; cited 2012 Apr 11]. Available from: http://www.genomeweb.com/rnai/allergan-drops-development-sirna-rx-amd-poor-phase-ii-data. Accessed June 21, 2012.
110. Quarkpharma. com [homepage on the Internet]. QPI-1002. California: Quark Pharmaceuticals, Inc.; c 2007 [updated 2010 Aug 18; cited 2012 Apr 10]. Available from: http://www.quarkpharma.com/qbi-en/products/QPI-1002da/. Accessed Jun 15, 2012.
111. TheFreeLibrary. com [homepage on the Internet]. Santaris Pharma A/S Advances a Second Drug From Its Cardiometabolic Program, SPC4955, Inhibiting apoB, into Phase 1 Clinical Trials for the Treatment of High Cholesterol. Pennsylvania: Farlex, Inc.; c 2012 [updated 2011 May 11; cited 2012 Apr 10]. Available from: http://www.thefreelibrary.com/Santaris+Pharma+A%2fS+Advances+a+Second+Drug+From+Its+Cardiometabolic.-a0256048995. Accessed May 11, 2012.
112. Pharmaceuticals A. Trial to Evaluate Safety and Tolerability of ALN-PCS02 in Subjects With Elevated LDL-Cholesterol (LDL-C). In: ClinicalTrials. gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; 2012 [updated 2012 Apr 20]. Available from: http://clinicaltrials.gov/ct2/show/NCT01437059?term=PCS02&rank=1. ClinicalTrials.gov Identifier: NCT01437059. Accessed Jul 11, 2012.
113. Santaris. com [homepage on the Internet]. Santaris Pharma A/S advances new cholesterol-lowering drug, SPC5001 inhibiting exciting new target PCSK9, into Phase 1 clinical trials for the treatment of high cholesterol. San Diego: Santaris Pharma A/S; c 2011 [updated 2011 May 4; cited 2012 Apr 9]. Available from: http://www.santaris.com/news/2011/05/04/santaris-pharma-advances-new-cholesterol-lowering-drug-spc5001-inhibiting-exciting-n. Accessed Jun 25, 2012.
114. Tekmirapharm. com [homepage on the Internet]. Tekmira Pharmaceuticals Completes ApoB SNALP Phase 1 Clinical Trial. British Columbia: Tekmira Pharmaceuticals Corp.; c 2012 [updated 2010 Jan 7; cited 2012 Apr 10]. Available from: http://files.shareholder.com/downloads/ABEA-50QJTB/1754071349x0x425312/9b404e8f-82e2-48a8-ba61-71328539afd9/TKM_News_2010_1_7_General_Releases.pdf. Accessed Jun 29, 2012.
115. Giiresearch. com [homepage on the Internet]. Top Companies and Products in the RNA/DNA Therapy Products Market Forecasts: The challenge of turning technology into therapy. Kawasaki: Global Information, Inc.; c 1997-2007 [updated 2011 Aug 12; cited 2012 Apr 11]. Available from: http://www.giiresearch.com/report/kt55538-therapy-prod.html. Accessed Jun 26, 2012.
116. Abnnewswire. net [homepage on the Internet]. rHIV7-shI-TAR-CCR5RZ. New York: ABN Newswire; c 2012 [updated 2010 Nov 1; cited 2012 Apr 11]. Available from: http://www.abnnewswire.net/search.asp?cp=utf-8&lang=_c&site=press_c&client=press-search-cs&output=xml_no_dtd&proxystylesheet=press-search-cs&proxyreload=1&filter=p&getfields=*&way=abn&way=web&qu=rHIV7-shI-TAR-CCR5RZ&stype=press_c&image2.x=33&image2.y=10. Accessed Jun 18, 2012.
117. Pharmaceuticals A. Trial to Evaluate Safety and Tolerability of ALN-TTR01 in Transthyretin (TTR) Amyloidosis. In: ClinicalTrials. gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; 2012 [updated 2012 May 23]. Available from: http://clinicaltrials.gov/ct2/show/NCT01148953?term=Alnylam&rank=4. ClinicalTrials.gov Identifier: NCT01148953. Accessed Jul 11, 2012.